secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102386
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q2 net loss $15.7M; cash $127.1M funds operations into H1 2028
----------------------------------------------------------------------------

- Net loss $15.7M in Q2 2025 versus $17.0M in Q2 2024; R&D expenses fell to $12.2M from $14.7M.
- Cash and investments $127.1M at June 30, 2025, supporting operations and proof-of-concept readouts into first half 2028.
- BBI-355/BBI-825 combination arm of POTENTIATE trial open for enrollment; initial proof-of-concept data expected within cash runway.
- BBI-940 (novel kinesin program) IND submission on track for first half 2026; clinical data anticipated within existing cash timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025102386/0000950170-25-102386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025102386/bold-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer